Table 2.

Mean growth during the placebo-controlled seasonal intermittent preventive treatment trial in Senegalese preschool children from September to November in year 1 by intervention group and the occurrence of clinical malaria

	Clinical malaria*†	Intervention‡§	Control	Difference¶ (intervention – control)	P value
Weight (g/mo)	No	+130 ± 344 (437)	+53 ± 327 (277)		< 0.01
	Yes	+109 ± 301 (49)	+38 ± 365 (218)		0.22
	Both	+123 ± 340 (486)	+43 ± 344 (497)	+80 (+35, +125)	< 0.001
Triceps skinfold (mm/mo)	No	−0.37 ± 1.00	−0.59 ± 0.99		< 0.01
	Yes	−0.11 ± 1.04	−0.55 ± 1.03		< 0.01
	Both	−0.39 ± 1.01	−0.66 ± 1.01	+0.27 (+0.14, +0.39)	< 0.0001
Subscapular skinfold (mm/mo)	No	−0.16 ± 0.64	−0.35 ± 0.64		< 0.001
	Yes	−0.13 ± 0.61	−0.41 ± 0.57		< 0.01
	Both	−0.15 ± 0.64	−0.36 ± 0.62	+0.21 (+0.13, +0.28)	< 0.0001
Height (mm/mo)	No	+7.6 ± 7.4	+8.1 ± 7.1		0.35
	Yes	+7.1 ± 8.0	+6.6 ± 7.2		0.41
	Both	+7.2 ± 7.5	+7.6 ± 7.2	−0.4 (−1.3, +0.6)	0.43

^*Clinical malaria was defined as a body temperature > 37.5°C or a history of fever or vomiting within the previous 24 hours; no other obvious reason for the fever or vomiting; and a blood film positive for P. falciparum.

^†When broken down by malaria status (the Yes and No row for each of the four growth variables), the means were adjusted for child age and village of residency within GLM, because of differences in these variables between those with and without malaria.

^‡Values are means ± SD (N).

^§When broken down by arm of the trial (the Both row for each of the four growth variables), unadjusted means were compared using t tests, because the randomization ensured that the arms had similar characteristics.

^¶95% confidence interval in parentheses.